101999-45-5

Basic information

• Product Name: CHEMBRDG-BB 7932577
• Synonyms: CHEMBRDG-BB 7932577;2-(7-HYDROXY-2-OXO-2H-CHROMEN-4-YL)ACETAMIDE;2-(7-hydroxy-2-oxo-2H-chromen-4-yl)acetamide(SALTDATA: FREE);2H-1-Benzopyran-4-acetamide, 7-hydroxy-2-oxo-
• CAS NO: 101999-45-5
• Molecular Formula: C₁₁H₉NO₄
• Molecular Weight: 219.19
• Mol File: 101999-45-5.mol
• Article Data: 6

Chemical Properties

• Boiling Point: 548°C at 760 mmHg
• Flash Point: 285.2°C
• Appearance: /
• Density: 1.443g/cm³
• Vapor Pressure: 1.27E-12mmHg at 25°C
• Refractive Index: 1.637
• CAS DataBase Reference: CHEMBRDG-BB 7932577(CAS DataBase Reference)
• NIST Chemistry Reference: CHEMBRDG-BB 7932577(101999-45-5)
• EPA Substance Registry System: CHEMBRDG-BB 7932577(101999-45-5)

Safety Data

• Hazard Codes: Xn
• Statements: 22
• Hazardous Substances Data: 101999-45-5(Hazardous Substances Data)

Usage

InChI:InChI=1/C11H9NO4/c12-10(14)3-6-4-11(15)16-9-5-7(13)1-2-8(6)9/h1-2,4-5,13H,3H2,(H2,12,14)

Upstream product

• 15991-13-6 7-hydroxycoumarin-4-acetic acid methyl ester 
• 6950-82-9 2-(7-hydroxy-2-oxochromen-4-yl)acetic acid 
• 542-05-2 acetonedicarboxylic acid 
• 108-46-3 recorcinol 
• 74083-58-2 (7-hydroxy-2-oxo-2H-chromen-4-yl)-acetic acid ethyl ester 
• 1042423-58-4 C₁₁H₁₀NO₇P 

Downstream Products

• 911290-31-8 {7-[(3-chlorobenzyl)oxy]-2-oxo-2H-chromen-4-yl}acetonitrile 

Relevant articles and documents

Synthesis and rat lens aldose reductase inhibitory activity of some benzopyran-2-ones

-

Discovery of a novel class of potent coumarin monoamine oxidase B inhibitors: Development and biopharmacological profiling of 7-[(3-chlorobenzyl) oxy]-4-[(methylamino)methyl]-2H-chromen-2-one methanesulfonate (NW-1772) as a highly potent, selective, reversible, and orally active monoamine oxidase B inhibitor

In an effort to discover novel selective monoamine oxidase (MAO) B inhibitors with favorable physicochemical and pharmacokinetic profiles, 7-[(m-halogeno)benzyloxy]coumarins bearing properly selected polar substituents at position 4 were designed, synthesized, and evaluated as MAO inhibitors. Several compounds with MAO-B inhibitory activity in the nanomolar range and excellent MAO-B selectivity (selectivity index SI > 400) were identified. Structure-affinity relationships and docking simulations provided valuable insights into the enzyme-inhibitor binding interactions at position 4, which has been poorly explored. Furthermore, computational and experimental studies led to the identification and biopharmacological characterization of 7-[(3-chlorobenzyl)oxy]-4-[(methylamino)-methyl]-2H-chromen-2-one methanesulfonate 22b (NW-1772) as an in vitro and in vivo potent and selective MAO-B inhibitor, with rapid blood-brain barrier penetration, short-acting and reversible inhibitory activity, slight inhibition of selected cytochrome P450s, and low in vitro toxicity. On the basis of this preliminary preclinical profile, inhibitor 22b might be viewed as a promising clinical candidate for the treatment of neurodegenerative diseases.

Profiling of glycosidase activities using coumarin-conjugated glycoside cocktails

Glycosidases are a large subgroup of carbohydrate-processing enzymes that hydrolytically cleave the glycosidic bond. Glycans formed by the action of glycosidases are involved in various biological processes. Genetic abnormalities in glycosidases are associated with inherited diseases. Thus, characterization of the catalytic activities of glycosidases is of great importance. Herein, we describe a simple and rapid approach for determining glycosidase activity profiles using coumarin-conjugated glycoside cocktails.